Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery

April 02, 2025 at 08:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Signals One spans the entire “Design-Make-Test-Decide” R&D lifecycle and empowers researchers to address previously “undruggable” targets

Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle. The Signals One platform addresses the growing complexity of drug modalities research by delivering a complete solution that integrates advanced research capabilities and fosters collaboration in multidisciplinary workflows.

The Signals One offering provides scientists with an all-in-one solution for managing data across the “Design-Make-Test-Decide” R&D lifecycle. The platform incorporates sophisticated data processing workflows that encompass a range of common analytical tasks, including in vitro curve fitting, in vivo data analysis, and group comparisons. The Signals One offering also ensures assay data is standardized and AI-ready, allowing researchers to uncover hidden relationships and insights through advanced AI tools. As part of its strategic direction, Revvity Signals Software plans to add additional AI enhancements to the user experience, including semantic search, summarization assistants, and automated protocol writing, while continuing to safeguard sensitive intellectual property.

“With the Signals One platform, we are striving to support scientists across every step of the R&D lifecycle,” said Kevin Willoe, president of Revvity Signals Software. “This solution empowers researchers to develop more targeted, effective therapies with fewer side effects, helping scientists tackle previously ‘undruggable’ targets. The platform enables researchers to quickly eliminate ineffective options and move promising therapies toward clinical trials.”

The Signals One platform will be introduced at the Bio-IT World Conference & Expo, April 2-4, in Boston, Massachusetts.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.